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Leptin regulates energy balance and glucose homeo-
stasis. Shortly after leptin was identified, it was es-
tablished that obesity is commonly associated with
leptin resistance, though the molecular mechanisms
remain to be identified. To explore potential mecha-
nisms of leptin resistance, we employed organotypic
brain slices to identify candidate signaling pathways
that negatively regulate leptin sensitivity. We found
that elevation of adenosine 30, 50-monophosphate
(cAMP) levels impairs multiple signaling cascades
activated by leptin within the hypothalamus. Notably,
this effect is independent of protein kinase A activa-
tion. In contrast, activation of Epac, a cAMP-regu-
lated guanine nucleotide exchange factor for the
small G protein Rap1, was sufficient to impair leptin
signaling with concomitant induction of SOCS-3
expression. Epac activation also blunted leptin-
induced depolarization of hypothalamic POMC
neurons. Finally, central infusion of an Epac activator
blunted the anorexigenic actions of leptin. Thus, acti-
vation of hypothalamic cAMP-Epac pathway is suffi-
cient to induce multiple indices of leptin resistance.
INTRODUCTION
Obesity arises when energy intake chronically exceeds energy
expenditure. Obesity is associated with several comorbidities,
including type 2 diabetes mellitus, several types of cancer, and
cardiovascular disease (Gaede et al., 2008; Stamler et al.,
1993; Van Gaal et al., 2006). Reduction in body weight has
a beneficial impact on a number of metabolic and cardiovascular
risk factors. Thus, development of effective strategies to fight
obesity will reduce the incidence of a myriad of diseases. Leptin
is a hormone that plays a central role in the regulation of energy
balance and glucose homeostasis via activation of leptin recep-
tors, particularly within the central nervous system (Bjørbaek and
Kahn, 2004; Flier, 2006; Friedman, 2004; Zhang et al., 1994).
Leptin administration decreases food intake, reduces body
weight, and increases systemic insulin sensitivity when adminis-
trated to lean humans and animals. However, nearly all forms of
obesity are associated with higher levels of circulating leptin
(Considine et al., 1996; Frederich et al., 1995; Maffei et al.,Ce1996). Thus, obese humans and animals display a decreased
response to endogenous and exogenous leptin. This has been
demonstrated by several measures, including attenuated
anorectic responses, reduction of both signal transducers and
activators of transcription (STAT) 3 phosphorylation, and neuro-
peptide release after leptin administration (Bjørbaek and Kahn,
2004; Enriori et al., 2007; Flier, 2006; Friedman, 2004; Mu¨nzberg
et al., 2004; Zhang et al., 1994). Thus, understanding the molec-
ular mechanisms underlying and developing strategies to
combat ‘‘leptin resistance’’ is a major goal of obesity research.
Cellular leptin resistance may bemediated by negative regula-
tory pathways of leptin receptor signaling. Indeed, recent studies
have identifiedmolecules that act as negative regulators of leptin
signaling. These include suppressor of cytokine signaling-3
(SOCS-3) (Bjørbaek et al., 1999; Howard et al., 2004;
Mori et al., 2004), protein tyrosine phosphatase 1B (PTP1B)
(Banno et al., 2010; Bence et al., 2006; Cook and Unger, 2002;
Zabolotny et al., 2002), and inflammatory signals such as
IKKb/NFkB and ER stress (Ozcan et al., 2009; Zhang et al.,
2008). However, the signaling networks that confer central leptin
resistance remain to be fully established. Therefore, delineation
of cellular signaling networks responsible for leptin sensitivity is
a high priority.
Accumulating evidence suggests that adenosine 30, 50-mono-
phosphate (cAMP) generally suppresses proinflammatory cyto-
kine signaling (Serezani et al., 2008). Numerous studies have
demonstrated that cAMP plays a role as a downregulator of
IL-6 signaling which uses JAK-STAT3 signaling (Bousquet
et al., 2001; Delgado and Ganea, 2000; Fasshauer et al., 2002;
Gasperini et al., 2002; Sands et al., 2006). Previous studies
showed that leptin reduces cAMP levels through activation of
phosphodiesterase 3B in pancreatic beta cells (Zhao et al.,
1998) and in the brain (Sahu and Metlakunta, 2005; Zhao,
2005; Zhao et al., 2002). Leptin and its receptor are structurally
and functionally related to the proinflammatory cytokine IL-6
cytokine family (Tartaglia, 1997). Thus, we hypothesized that
cAMP-related signal might interfere with leptin signaling path-
ways and could be involved in central leptin resistance.
Classically, cAMP acts through cAMP-dependent protein
kinase (PKA) (Daniel et al., 1998). However, it is unsettled
whether or not PKA mediates the inhibitory effects of cAMP on
the JAK-STAT3 pathway (Bousquet et al., 2001; Gasperini
et al., 2002; Sands et al., 2006). cAMP also acts through Epac
(exchange protein directly activated by cAMP), the guanine
nucleotide-exchange factor for the small GTPase Rap1(de Rooij
et al., 1998; Gloerich and Bos, 2010). Notably, Epac-mediated
activation of Rap1 induces SOCS-3 expression in endothelialll Metabolism 13, 331–339, March 2, 2011 ª2011 Elsevier Inc. 331
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Figure 1. Leptin Signaling in Organotypic
Hypothalamic Slices
(A) Leptin-induced pSTAT3 in the slices. The slices
were prepared from mice and maintained for
10 days. The slices were treated with either leptin
(100 nM) or saline for 30 min and fixed with 4%
formalin and subjected to immunohistochemistry
with anti-pSTAT3 antibodies followed by DAB
staining. The presence of pSTAT3-labeled cells is
evident in the arcuate nucleus (Arc) and the ventro-
medial hypothalamic nucleus (VMH) of the slices
treated with leptin.
(B) Western blotting of hypothalamic pSTAT3 by
leptin. The slices treated with leptin or saline for
30 min were extracted and subjected to western
blot with antibodies against pSTAT3 and pS6K.
(C) Dose-dependent phosphorylation of STAT3 by
leptin. The slices were incubated with an in-
creasing dose of leptin for 30 min and then stained
with an anti-pSTAT3 antibody as in (A). pSTAT3
signal within the Arc was measured. Results
were plotted as the fold increase relative to the
control (0 nM). Values are presented as mean ±
standard error of the mean (SEM); ***p < 0.001,
compared to 0 nM for t test, *p < 0.05 for one-
way ANOVA.
(D) Absent of pSTAT3 by leptin in the leptin
receptor null mice. The slices prepared from
wild-type mice or leptin receptor knockout mice
(Coppari et al., 2005) were treated with leptin
(100 nM) or saline for 30 min and then stained
with anti-pSTAT3 antibodies.
(E) Quantification of (D). Values are presented as
mean ± SEM; **p < 0.01 for two-way ANOVA.
See also Figure S1.
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cAMP to the JAK-STAT3 pathway has not yet been established.
To facilitate the identificationofpossiblesignalingpathways that
contribute to leptin resistance,weestablishedan in vitro systemof
leptin action in the hypothalamus. We used an organotypic slice
culture system,which enabled adirect assessment andmanipula-
tion of candidate molecular pathways inducing leptin resistance
within hypothalamicneurons.Byemploying this system,we inves-
tigatedwhether activationof cAMP-dependent pathways induced
leptin resistance in our hypothalamic slice model.
RESULTS AND DISCUSSION
Signaling from the Leptin Receptor in Organotypic
Hypothalamic Slices
Organotypic slices of mouse hypothalamus were prepared and
then maintained at an air-media interface on Millicell-CM filters
in MEM base medium for 10 days. We first validated the model
system by assessing the effects of leptin treatment of the slices.
We found that leptin induced robust phosphorylation of STAT3
(Figures 1A and 1B). In contrast, no STAT3 phosphorylation
was observed in the saline-treated slices (Figures 1 A and 1B),
as shown by both immunohistochemistry and western blot332 Cell Metabolism 13, 331–339, March 2, 2011 ª2011 Elsevier Inc.analysis with an anti-phospho-STAT3 antibody. Notably, leptin-
inducedphosphorylationofSTAT3wasonly seen in hypothalamic
nuclei such as arcuate nucleus (Arc) and the ventromedial hypo-
thalamus (VMH), known to express leptin receptors (Elmquist
et al., 2005; Scott et al., 2009) (Figure 1A). Treatment of organo-
typic slices with leptin also led to phosphorylation of S6K (Fig-
ure 1B), another mediator of leptin action (Cota et al., 2006). We
confirmed that leptin-induced STAT3 phosphorylation is medi-
ated via the leptin receptor, by using slices prepared from the
leptin receptor null (Leprneo/neo mice) mice (Figures 1D and 1E)
(Coppari et al., 2005). Collectively, these results demonstrate
that the in vitro system is a model of leptin-induced STAT 3 and
S6K activation. We also tested whether this model system was
able to recapitulate leptin-induced leptin resistance (Myers
et al., 2010). We found that pretreatment of slices with higher
levels of leptin (120 nM for 6 hr) strongly impaired leptin-induced
pSTAT3 (Figure S1 available online). This indicates that an
in vitro system can mimic leptin-induced leptin resistance.
Cyclic AMP Impairs Leptin Signaling
in Hypothalamic Neurons
To investigate whether cAMP impairs the leptin signaling path-
ways in the hypothalamus, we utilized pharmacological reagents
Cell Metabolism
Leptin Resistance by cAMP-Related Signalingtomodulate cellular cAMP levels in slices. Interestingly, we found
that treatment of the slices with both forskolin (an adenylate
cyclase activator; Fsk [20 mM]) plus low level of leptin (0.5 nM))
(Fsk/Lep) had a potent inhibitory effect on leptin-induced
STAT3 phosphorylation in the whole hypothalamus (Figures
2A–2D) and in the arcuate nucleus (Figure 2G). This was in
contrast to the robust STAT3 phosphorylation observed in
control slices (Figure 2A). Forskolin alone clearly blunted leptin-
induced STAT3 phosphorylation (Figure 2B), and this effect
was enhanced by the presence of low levels of leptin (0.5 nM)
(Figure 2B). Treatment of the slices with the low dose of leptin
(0.5 nM) alone had little inhibitory effect on leptin-STAT3
signaling as this dose did not elicit STAT3 phosphorylation at
either 30 min or 6 hr (Figure 2B).
To further investigate potential signaling pathways involved,
we used two different types of phosphodiesterase (PDE) inhibi-
tors known to elevate intracellular cAMP levels: IBMX, a nonspe-
cific inhibitor of PDE, and cilostamide, a selective inhibitor for
PDE3. Both PDE inhibitors enhanced the inhibitory effects of for-
skolin on leptin-induced STAT3 phosphorylation (Figure 2C). We
also found that Fsk/Lep also dampened the leptin-induced
phosphorylation of S6 Kinase (Figure 2D), a response that is
also impaired in the high-fat diet-induced obese rodents (Cota
et al., 2008). Notably, Fsk/Lep treatment increased hypothalamic
SOCS-3 and PTP1B at the levels of protein and messenger RNA
(mRNA) (Figures 2E and 2F), both of which have been demon-
strated to contribute to leptin resistance (Bence et al., 2006;
Bjørbaek et al., 1999; Cook and Unger, 2002; Howard et al.,
2004; Mori et al., 2004; Zabolotny et al., 2002).
Cyclic AMP-Induced Inhibitory Effect
Is Independent of PKA
We next dissected potential downstream pathways mediating
the inhibitory effects of Fsk/Lep on signaling from the leptin
receptor. Classically, cAMP exerts many of its effects through
protein kinase A (PKA) (Daniel et al., 1998). Thus, we tested
whether the inhibitory action of cAMP is mediated in a PKA-
dependent manner. Treatment of slices with an inhibitor of
PKA, H89, had no effect on cAMP inhibition of leptin-induced
phosphorylation of STAT3 and S6K (Figure 2H). Fsk/Lep also
induced hypothalamic SOCS-3 in the presence of H 89, a PKA
inhibitor (Figure 2I). These results suggest that elevations of
cAMP negatively regulate leptin signaling in a PKA-independent
manner.
Activation of Epac Blunts Leptin Signaling
in the Hypothalamus
In addition to the PKA pathway, increased cAMP also activates
an alternative pathway via Epac, a guanine nucleotide exchange
factor, which activates a small G protein Rap1 (de Rooij et al.,
1998). We found that Fsk/Lep treatment activated endogenous
Rap1 in the hypothalamus (Figure S3). Thus, we next examined
whether activation of the Epac-Rap1 pathway is sufficient to
evoke an inhibitory effect on leptin receptor signaling. We used
a hydrolysis-resistant Epac activator [8-(4-chlorophenylthio)-
20-O-methyladenosine-30, 50-cyclic monophosphorothioate,
8-pCPT-20-O-Me-cAMP] that selectively binds and activates
Epac (Enserink et al., 2002). Treatment of the slices with
8-pCPT-20-O-Me-cAMP plus low level of leptin (8-pCPT-20-O-CeMe-cAMP/Lep) impaired leptin-induced phosphorylation of
STAT3 (Figures 3A and 3B). Either leptin or 8-pCPT-20-O-Me-
cAMP alone had little effect on leptin-dependent pSTAT3 phos-
phorylation (Figure 3C). Epac activation also blunted the ability of
leptin to modulate other cellular signaling of leptin: phosphoryla-
tion of S6K (Figures 3D and 3E) within the hypothalamus. Further,
we found that 8-pCPT-20-O-Me-cAMP induced SOCS-3 and
PTP1B (Figures 3F and 3G). This induction occurred in a dose-
dependent manner in the presence of low level of leptin, which
alone had no effect on induction of either protein (Figure 3H).
Collectively, these data suggest that activation of cAMP-
Epac/Rap1 impairs hypothalamic leptin receptor signaling.
Cyclic AMP Does Not Interfere with CNTF
Phosphorylation of STAT3 in the Hypothalamus
Recent studies have shown that ciliary neurotrophic factor
(CNTF) and leptin have similar anorectic effects (Gloaguen
et al., 1997) by modulating similar intracellular signaling
cascades. In addition, CNTF can activate leptin-like signaling
pathways and can reduce body weight in leptin-resistant obesity
(Gloaguen et al., 1997; Lambert et al., 2001). To determine
whether the cAMP-Epac pathway is specifically involved in leptin
resistance, we assessed whether CNTF induction of STAT3
phosphorylation was blunted by activation of Epac. We found
that CNTF caused STAT3 phosphorylation in hypothalamic
slices even after Fsk/Lep pretreatment of the slices (Figure S4A).
cAMP signaling has been reported to interfere with interleukin 6
(IL-6)-STAT3 signaling in different cell lines (Bousquet et al.,
2001; Delgado and Ganea, 2000; Fasshauer et al., 2002;
Gasperini et al., 2002; Sands et al., 2006). Thus, we tested
whether elevation of cAMP impaired IL6-induced STAT3 phos-
phorylation in our system. As expected, Fsk/Lep pretreatment
blocked IL-6 dependent STAT3 phosphorylation (Figure S4B).
Activation of the cAMP-Epac Pathway Impairs
Leptin-Induced Depolarization of POMC Neurons
We also employed electrophysiological approach to assess the
potential inhibitory effects of cAMP-Epac signaling on leptin’s
cellular actions. We assessed the ability of leptin to directly acti-
vate pro-opiomelanocortin (POMC) neurons, which are identified
targets of leptin. In order to identify POMCneurons for whole-cell
patch-clamp recordings, we used POMC-GFP mice (Parton
et al., 2007; Ramadori et al., 2008). Whole-cell patch-clamp
recordings were performed to assess the effects of leptin on
membrane potential. In agreement with previous reports
(Cowley et al., 2001; Hill et al., 2008; Williams et al., 2010), leptin
caused rapid depolarization from rest in 8 of 12 POMCneurons in
organotypic slices (6.4 ± 0.6 mV; resting membrane potential,
–51.7 ± 1.3 mV; n = 8; Figures 4A and 4B). We next used organo-
typic slices from POMC-GFP mice that were pretreated for 6 hr
with either Fsk/Lep or 8-pCPT-20-O-Me-cAMP/Lep. We found
that pretreatment with Fsk/Lep prevented the leptin induced
depolarization in all POMC neurons examined (0.8 ± 0.3 mV,
n = 13; resting membrane potential, –51.3 ± 2.3 mV; n = 13; Fig-
ure 4A and 4B). Similarly, leptin failed to depolarize POMC
neurons of slices pretreated with 8-pCPT-20-O-Me-cAMP/Lep
(0.6 ± 0.6 mV; resting membrane potential, –50.3 ± 1.0 mV;
n = 12; Figures 3A and 3B). Notably, the low dose of leptin alone
failed to inhibit the leptin-induced depolarization of POMCll Metabolism 13, 331–339, March 2, 2011 ª2011 Elsevier Inc. 333
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Leptin Resistance by cAMP-Related Signalingneurons (5.8 ± 0.6mV; resting membrane potential, 52.2 ±
1.5mV; Figures 4A and 4B). Additionally, in the presence of tetro-
dotoxin, which blocks action potential-mediated synaptic trans-
mission, Fsk/Lep still prevented leptin-induced depolarization of
POMC neurons (0.5 ± 0.5mV; resting membrane potential,
49.9 ± 1.3mV; Figures 4A and 4B). Collectively, these data
suggest that activation of cAMP-Epac signaling directly desensi-
tizes POMC neurons to leptin, which is independent of action
potential-mediated synaptic transmission.
Activation of Brain Epac-Rap1 Pathway Causes Central
Leptin Resistance In Vivo
To provide further insights to the functional significance of the
Epac pathway as it relates to leptin signaling in vivo, we tested
whether activation of the Epac pathway impairs the ability of
exogenous leptin to inhibit food intake. We performed intracere-
broventricular (ICV) infusions of a selective Epac activator
(8-pCPT-20-O-Me-cAMP) in chow fed lean mice. We first identi-
fied a dose of 8-pCPT-20-O-Me-cAMP (5 mg) that did not alter
food intake. We next evaluated the ability of ICV leptin injections
to suppress food intake following an ICV pretreatment with this
dose of the Epac activator. As expected, leptin treatment mark-
edly reduced food intake in mice pretreated with vehicle (Fig-
ure 4C). In contrast, in the mice pretreated with the Epac
activator leptin did not significantly reduce food intake 4 hr after
leptin injection (Figure 4C). These results suggest that the acute
anorexic responses to exogenous leptin are blunted by prior
central infusions of an activator of the Epac-Rap1 pathway.
Finally, we assessed Rap1 activity in the hypothalamus of obese
mice after chronic exposure to a high-fat diet. We found that
hypothalamic Rap1 activity is increased in the mice fed on high
fat diet for 4 weeks (Figure 4D), suggesting that the hypothalamic
Epac-Rap1 pathway is activated in the mice exposed to high fat.Figure 2. Inhibitory Effect of cAMP on Hypothalamic Leptin Signaling
(A) Inhibitory effect of Fsk/Lep on leptin-induced pSTAT3. The organotypic slices
(Fsk/Lep [20 mM/0.5 nM]) for 6 hr and then stimulated with or without leptin (100 n
(pY705).
(B) Inhibitory effect of Fsk is enhanced by the presence of low levels of leptin. The s
both Fsk and low levels of leptin for 6 hr were stimulated with leptin (100 nM for 30
Values are presented asmean ± SEM. Results were analyzed with one-way ANOV
***p < 0.001; compared to Lep stimulation, **p < 0.01, 0.01 < *p < 0.05.
(C) Phosphodiesterase inhibitors enhanced the inhibitory effects of forskolin on lep
(25 mM) with Fsk (20 mM) had a stronger inhibitory effect on the leptin-induced STA
as in (B) instead of using low levels of leptin. Values are presented as mean ± SE
comparison test. Control versus Lep stimulation, ***p < 0.001; compared to Lep
(D) The effect of Fsk/Lep on hypothalamic lepin signaling pathways. Left: The slic
were stimulated with or without leptin (100 nM for 30min). The hypothalami were c
pSTAT3, pS6K, SOCS-3, and PTP1B. Right: Quantification by image analysis of h
SEM. For pstat3, 11 separate experiments, **p (–) versus Lep, p = 0.0015 for two-
for two-way ANOVA.
(E) Fsk/Lep induction of SOCS3. Top: Quantification by image analysis of hypoth
Wilcoxon signed rank test. Bottom: Relative levels of hypothalamic Socs-3mRNA
*p < 0.05 for Tukey’s multiple comparison test.
(F) Fsk/Lep induction of PTP1B. Top: Quantification by image analysis of
0.01 < *p < 0.05 for Wilcoxon signed rank test. Bottom: Relative levels of hypoth
(G) Quantification of STAT3 phosphorylation in the arcuate nucleus. Eight arcua
western blot with anti-pSTAT3 antibodies; p = 0.0288 for two-way ANOVA, *p <
(H) Fsk/Lep’s inhibitory effect is independent of PKA. Treatment with Fsk/lep blu
(I) Fsk/Lep induction of SOCS3 occurred in the presence or absence of varying d
See also Figure S2.
CeCollectively, our in vitro and in vivo results support the model
that activation of the cAMP-Epac pathway induces cellular leptin
resistance within hypothalamic neurons, a critical site of leptin
action. Activation of the cAMP-Epac pathway blunted signaling
pathways downstream from the leptin receptor, including
JAK-STAT3, mTOR-S6K, ERK, and AMPK. Thus, signaling
systems downstream of the leptin receptor are negatively regu-
lated by the cAMP-Epac pathway. Notably, activation of Epac
induced SOCS-3 and PTP1B, two negative regulators of leptin
signaling in vivo (Banno et al., 2010; Bence et al., 2006; Bjørbaek
et al., 1999; Cook and Unger, 2002; Howard et al., 2004; Mori
et al., 2004; Zabolotny et al., 2002). Our study is also consistent
with a previous report that cilostamide, an inhibitor for phospho-
diesterase 3B, inhibited leptin-induced suppression of food
intake and STAT3 phosphorylation (Zhao et al., 2002). Taken
together, our findings provide evidence linking the cAMP-Epac
pathway to central leptin resistance, as seen in obesity.
One implication of our results is that leptin resistance may be
induced by a broad range of extracellular stimuli that can activate
the cAMP-Epac-Rap1 pathway. For example, any G protein-
coupled receptors that act through either Gs or Gi would be
apotential target toperturb intracellular cAMP levels (Nevesetal.,
2002). Thus, we tested whether a-MSH, an agonist of melano-
cortin receptors MC3R and MC4R impairs leptin-induced
pSTAT3, since MC3R and MC4R activate Gs and are
expressed in POMC and NPY neurons (Cone, 2005). However,
we did not detect an inhibitory effect of a-MSH pretreatment
on subsequent leptin signaling in our slices (data not shown).
Thus, to date we have not found a ‘‘physiological’’ regulator
that drives both activation of the pathway and leptin resistance.
However, our findings support the notion that cAMP-Epac
signalingmay contribute leptin resistance in obesity, aswe found
elevations of Epac signaling in the hypothalamus of the mice fedPathways
were pretreated with DMSO/saline (Control) or forskolin plus low levels of leptin
M) for 30 min. The slices were fixed and stained with an anti-pSTAT3 antibody
lices that were preincubated with saline, forskolin, or low levels of leptin or with
min). pSTAT3 immunostaining signal was quantified as described in Figure 1B.
A followed by Tukey’smultiple comparison test. Control versus Lep stimulation,
tin-induced STAT3 phosphorylation. Treatment of cilostamide (25 mM) or IBMX
T3 phosphorylation than Fsk treatment alone. The experiment was performed
M. Results were analyzed with one-way ANOVA followed by Tukey’s multiple
stimulation, 0.01 < *p < 0.05, **p < 0.01.
es that were preincubated with either saline or Fsk/Lep (20 mM/0.5 nM for 6 hr)
ut out and then extracted and subjected to western blot with antibodies against
ypothalamic STAT3 and S6K phosphorylation. Values are presented as mean ±
way ANOVA; for pS6K, six different experiments, **p (–) versus Lep, p = 0.0002
alamic SOCS-3 protein. Sixteen separate experiments, 0.001 < **p < 0.01 for
measured by real-time PCR; p = 0.0031 for oneway ANOVA, 0.001 < **p < 0.01,
hypothalamic PTP1B protein. Ten separate experiments were performed.
alamic ptp1b mRNA measured by real-time PCR; *p < 0.05 for t test.
te nuclei were collected per group. Proteins were extracted and subjected to
0.05 for t test.
nted leptin signaling in the presence of H-89, an inhibitor for PKA.
osages of H-89.
ll Metabolism 13, 331–339, March 2, 2011 ª2011 Elsevier Inc. 335
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Figure 3. Activation of Epac Sufficiently Blunts Hypothalamic Leptin Signaling Pathways
(A) Inhibitory effect of an Epac agonist (8-pCPT-20-O-Me-cAMP)/Lep on leptin-induced pSTAT3. An Epac agonist (100 mM) with a low level of leptin (0.5 nM) for
6 hr impaired leptin- (100 nM for 30 min) induced STAT3 phosphorylation in the hypothalamus.
(B) Quantification of pSTAT3 signal in (A). pSTAT3 immunostaining signal was quantified as described in Figure 1B. Values are presented as mean ± SEM;
***p < 0.001, compared to 0 nM for t test.
(C) Treatment of 8-pCPT-20-O-Me-cAMP (100 mM) plus a low level of leptin (0.5 nM) had a stronger inhibitory effect on the leptin-induced STAT3 phosphorylation
than 8-pCPT-20-O-Me-cAMP treatment alone.
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Leptin Resistance by cAMP-Related Signalingwith high-fat diet. Clearly, further studies are required to deter-
mine whether the Epac-Rap1 pathway is required to maintain
leptin sensitivity in vivo. Nonetheless, perturbation of Epac-
Rap1 signaling may contribute to the pathophysiology of leptin
resistance.
SUPPLEMENTAL INFORMATION
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Figure 4. Activation of the cAMP-Epac
Pathway Impairs the Leptin-Induced
Depolarization of POMC Neurons
(A) Current-clamp recordings demonstrated that
activation of Epac signaling occluded the leptin-
induced depolarization of POMC neurons from
rest. Leptin-induced (100 nM) depolarization of
POMC neurons of organotypic slices that were
pretreated for 6 hr with either saline (control, top
left), a low level of leptin alone (0.03 nM, top right),
TTX (0.5 mM, middle left), Fsk/Lep (20 mM/0.03 nM,
middle right), TTX/Fsk/Lep (0.5 mM /20 mM/0.03
nM, bottom left) or Epac agonist (8-pCPT-20-O-
Me-cAMP)/Lep (100 mM/0.03 nM, bottom right).
(B) Leptin-induced responses of identified POMC
neurons pretreated with the indicated reagents. p
values compared with the WT are shown. Values
are presented as mean ± SEM. Comparisons
between two groups were made by unpaired
Student’s t test. p < 0.05 was considered to be
statistically significant.
(C) Activation of Epac induces central leptin resis-
tance. Male C57BL/6 mice were randomly
assigned to four weight-matched groups (26.09 ±
1.59 g for Veh/Veh, 26.34 ± 1.96 g for Veh/Lep,
26.03 ± 2.01 g for 8-pCPT-20-O-Me-cAMP/Veh,
or 26.54 ± 2.10 g for 8-pCPT-20-O-Me-cAMP/
Lep, p = 0.8938 for one-way ANOVA). The mice
were first injected ICV into the lateral ventricle
with vehicle or 5 mg 8-pCPT-20-O-Me-cAMP fol-
lowed by 4 hr later by second injection of either
vehicle or leptin (5 mg). The cumulative food intake
was measured for 4 hr and 24 hr after the second
injection. Values are presented as mean ± SEM.
Results were analyzed with one-way ANOVA fol-
lowed by Tukey’s multiple comparison test;
p = 0.0062 (4 hr) and p < 0.0001 (24 hr) for one-
way ANOVA; ***p < 0.001 and **p < 0.01 compared
to Veh/Veh, *p < 0.05 compared to 8-pCPT-20-O-
Me-cAMP/Veh.
(D) Exposure to a high-fat diet for 4 weeks
increases Rap1 activity in the hypothalamus.
Hypothalamic Rap1 activity was assessed in the
mice either fed with high-fat diet or normal chow
for 4 weeks. Values are presented as mean ±
SEM; **p < 0.01, compared to NC for t test.
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